.png){kind=spacer}
Meet Picopoint Genomics at the American Association for Cancer Research®️ (AACR) Annual Meeting 2026
San Diego Convention Centre | Booth #4916 (Hall G)
Discover how the PicoceptionTM platform extracts deep gene profiles from old, tiny & challenging samples at to 2-3X faster turnaround.
Picoception is designed especially for degraded RNA from FFPE tissue or extracted RNA as input.
- Unlock insights from large clinical cohorts & the smallest biopsies.
- Evaluate the transcriptome of tumor epithelial & microenvironment compartments.
Not affiliated with or endorsed by AACR.
Posters at AACR
- Development of a gene expression predictor for bevacizumab response
April 20, 2 - 5pm | Section 41, Board 3 | Link to Abstract - Validation of microenvironment gene signatures from FFPE to predict nasopharyngeal cancer prognosis
April 21, 9am - 12pm | Section 47, Board 1 | Link to Abstract
Here are some examples of how Picoception has been applied:
Here are some examples of how Picoception has been applied:
Identify deep gene expression differences & disease subtypes from tiny amounts of FFPE tissue
Profile tumor epithelium & microenvironment from old tissue sections with no batch effect
Develop & validate biomarkers from clinical trial cohorts
We provide a variety of services, direct from tissue or direct from RNA, and can also design a customized approach if you already have a clinical development strategy in mind.
Meet our Team
Joshua Tay, CSO
PhD (Cancer Biology), Stanford University, surgeon-scientist leading a translational lab focused on RNA clinical biomarker development across cancer and inflammatory conditions.
Joe Foley, CEO
PhD (Genomics), Stanford University, with deep expertise in molecular biology and gene expression profiling from degraded samples.
Schedule a discussion at AACR below, Whatsapp us here, or e-mail cavin@picopoint.bio.